Plaintiff
6 cases as plaintiff.
The Cigna Group is an American multinational managed healthcare and insurance company. Headquartered in Bloomfield, Connecticut, the company was formed in 1982 through the merger of Connecticut General Life Insurance Company and INA Corporation. The Cigna Group is a publicly traded company on the NYSE under the ticker symbol "CI" and in 2024, reported total revenues of approximately $247.1 billion and employed around 73,500 people. As of December 31, 2025, it had over 185 million customer relationships across more than 30 markets and jurisdictions.
The Cigna Group operates through two primary divisions: Cigna Healthcare and Evernorth Health Services. Cigna Healthcare provides comprehensive medical, dental, disability, life, and accident insurance products and services, primarily offered through employers. Evernorth Health Services focuses on pharmacy benefits management, specialty pharmacy services, home delivery pharmacy, and various care delivery and management solutions for health plans, employers, and government organizations.
In terms of patent litigation, The Cigna Group appears to be an operating company that primarily defends against patent infringement suits. The provided data shows one tracked case where The Cigna Group is a defendant and zero cases where it is a plaintiff. This single case, Damaka, Inc. v. The Cigna Group et al., is being litigated in the District Court, Eastern District of Texas, a venue often associated with patent assertion entity (PAE) litigation.
The sole tracked case, Damaka, Inc. v. The Cigna Group et al., filed on May 29, 2025, involves allegations of patent infringement related to communication, audio, and video capabilities in computer applications. Damaka, Inc. has asserted patents generally covering methods for A/V capabilities on computers and applications, with the accused products including Cigna's MDLIVE application (desktop, Android, iOS, and iPad versions). Damaka, Inc. also filed a separate complaint against Cisco Systems Inc. around the same time, asserting related patents. Patents assigned to Damaka, Inc. cover areas such as scalable browser-based audio/video conferencing and providing additional functionality to existing software.
Watchlist
Email-only, free, anonymous. We'll notify you when The Cigna Group files another patent-infringement lawsuit. One-click unsubscribe from any alert.
Follow-on antitrust suit alleging Sherman Act § 2 monopolization. Complaint alleges the '427 was expressly taught in prior art and issued after a purportedly false Tutino Declaration, and that Celgene withdrew its '427 infringement claims before most settlements.
Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; The Cigna Group sued Celgene in D.N.J. Status is generally pending/consolidated.
Antitrust monopolization suit challenging Celgene's Pomalyst crystalline-form patents, including the '647/'648/'649 patents; Celgene/BMS moved to dismiss.
Antitrust action in S.D.N.Y. naming the '939 formulation patent as part of an alleged monopolization scheme. Pending.
Antitrust/purchaser-overcharge action against Celgene and Bristol Myers Squibb. The complaint references the '3939 patent and the method-of-treatment patent tree as part of the alleged monopolization scheme. Case is pending.
Antitrust action by The Cigna Group against Celgene Corp. in the Pomalyst antitrust litigation; complaints dismissed March 2025, judgment entered for defendants March 2026, and appeal to the Second Circuit filed April 2026.